journal
MENU ▼
Read by QxMD icon Read
search

Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology

journal
https://www.readbyqxmd.com/read/29792754/loss-of-chromosome-18q11-2-q12-1-is-predictive-for-survival-in-patients-with-metastatic-colorectal-cancer-treated-with-bevacizumab
#1
Erik van Dijk, Hedde D Biesma, Martijn Cordes, Dominiek Smeets, Maarten Neerincx, Sudipto Das, Paul P Eijk, Verena Murphy, Anna Barat, Orna Bacon, Jochen H M Prehn, Johannes Betge, Timo Gaiser, Bozena Fender, Gerrit A Meijer, Deborah A McNamara, Rut Klinger, Miriam Koopman, Matthias P A Ebert, Elaine W Kay, Bryan T Hennessey, Henk M W Verheul, William M Gallagher, Darran P O'Connor, Cornelis J A Punt, Fotios Loupakis, Diether Lambrechts, Annette T Byrne, Nicole C T van Grieken, Bauke Ylstra
Purpose Patients with metastatic colorectal cancer (mCRC) have limited benefit from the addition of bevacizumab to standard chemotherapy. However, a subset probably benefits substantially, highlighting an unmet clinical need for a biomarker of response to bevacizumab. Previously, we demonstrated that losses of chromosomes 5q34, 17q12, and 18q11.2-q12.1 had a significant correlation with progression-free survival (PFS) in patients with mCRC treated with bevacizumab in the CAIRO2 clinical trial but not in patients who did not receive bevacizumab in the CAIRO trial...
May 24, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29791291/additional-evidence-that-end-of-treatment-fluorodeoxyglucose-positron-emission-tomography-evaluation-is-necessary-in-advanced-hodgkin-lymphoma
#2
Charles Mesguich, Krimo Bouabdallah, Noël Milpied, Elif Hindié
No abstract text is available yet for this article.
May 23, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29791290/reply-to-h-j-a-adams-et-al-and-c-mesguich-et-al
#3
Andrea Gallamini, Simonetta Viviani, Chiara Pavoni, Alessandro Rambaldi
No abstract text is available yet for this article.
May 23, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29791289/minimally-invasive-lung-cancer-surgery-performed-by-thoracic-surgeons-as-effective-as-thoracotomy
#4
Daniel J Boffa, Andrzej S Kosinski, Anthony P Furnary, Sunghee Kim, Mark W Onaitis, Betty C Tong, Patricia A Cowper, Jessica R Hoag, Jeffrey P Jacobs, Cameron D Wright, Joe B Putnam, Felix G Fernandez
Purpose The prevalence of minimally invasive lung cancer surgery using video-assisted thoracic surgery (VATS) has increased dramatically over the past decade, yet recent studies have suggested that the lymph node evaluation during VATS lobectomy is inadequate. We hypothesized that the minimally invasive approach to lobectomy for stage I lung cancer resulted in a longitudinal outcome that was not inferior to thoracotomy. Patients and Methods Patients > 65 years of age who had undergone lobectomy for stage I lung cancer between 2002 and 2013 were analyzed within the Society of Thoracic Surgeons General Thoracic Surgery Database, which had been linked to Medicare data, as part of a retrospective-cohort, noninferiority study...
May 23, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29791288/strikingly-heterogeneous-results-among-studies-on-interim-fluorodeoxyglucose-positron-emission-tomography-adapted-treatment-in-advanced-stage-hodgkin-lymphoma
#5
Hugo J A Adams, Thomas C Kwee
No abstract text is available yet for this article.
May 23, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29791287/brca1-2-mutations-and-bevacizumab-in-the-neoadjuvant-treatment-of-breast-cancer-response-and-prognosis-results-in-patients-with-triple-negative-breast-cancer-from-the-geparquinto-study
#6
Peter A Fasching, Sibylle Loibl, Chunling Hu, Steven N Hart, Hermela Shimelis, Raymond Moore, Christian Schem, Hans Tesch, Michael Untch, Jörn Hilfrich, Mahdi Rezai, Bernd Gerber, Serban Dan Costa, Jens-Uwe Blohmer, Tanja Fehm, Jens Huober, Cornelia Liedtke, Richard M Weinshilboum, Liewei Wang, James N Ingle, Volkmar Müller, Valentina Nekljudova, Karsten E Weber, Brigitte Rack, Matthias Rübner, Gunter von Minckwitz, Fergus J Couch
Purpose BRCA1/2 mutations are frequent in patients with triple-negative breast cancer (TNBC). These patients are often treated with primary systemic chemotherapy. The aim of this study was to analyze the effects of BRCA1/2 mutations on pathologic complete response (pCR) and disease-free survival (DFS) in a cohort of patients with TNBC treated with anthracycline and taxane-containing chemotherapy, with or without bevacizumab. Patients and Methods Germline DNA was sequenced to identify mutations in BRCA1 and BRCA2 in 493 patients with TNBC from the GeparQuinto study...
May 23, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29791286/metastatic-pancreatic-cancer-asco-clinical-practice-guideline-update
#7
Davendra P S Sohal, Erin B Kennedy, Alok Khorana, Mehmet S Copur, Christopher H Crane, Ignacio Garrido-Laguna, Smitha Krishnamurthi, Cassadie Moravek, Eileen M O'Reilly, Philip A Philip, Ramesh K Ramanathan, Joseph T Ruggiero, Manish A Shah, Susan Urba, Hope E Uronis, Michelle W Lau, Daniel Laheru
Purpose In 2016, ASCO published a guideline to assist in clinical decision making in metastatic pancreatic cancer for initial assessment after diagnosis, first- and second-line treatment options, palliative and supportive care, and follow-up. The purpose of this update is to incorporate new evidence related to second-line therapy for patients who have experienced disease progression or intolerable toxicity during first-line therapy. Methods ASCO convened an Expert Panel to conduct a systematic review of the literature on second-line therapy published between June 2015 and January 2018...
May 23, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29791285/cardiac-structure-injury-after-radiotherapy-for-breast-cancer-cross-sectional-study-with-individual-patient-data
#8
Carolyn Taylor, Paul McGale, Dorthe Brønnum, Candace Correa, David Cutter, Frances K Duane, Bruna Gigante, Maj-Britt Jensen, Ebbe Lorenzen, Kazem Rahimi, Zhe Wang, Sarah C Darby, Per Hall, Marianne Ewertz
Purpose Incidental cardiac irradiation can cause cardiac injury, but little is known about the effect of radiation on specific cardiac segments. Methods For 456 women who received breast cancer radiotherapy between 1958 and 2001 and then later experienced a major coronary event, information was obtained on the radiotherapy regimen they received and on the location of their cardiac injury. For 414 women, all with documented location of left ventricular (LV) injury, doses to five LV segments were estimated. For 133 women, all with documented location of coronary artery disease with ≥ 70% stenosis, doses to six coronary artery segments were estimated...
May 23, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29791284/risk-imaging-mismatch-in-cardiac-imaging-practices-for-women-receiving-systemic-therapy-for-early-stage-breast-cancer-a-population-based-cohort-study
#9
Paaladinesh Thavendiranathan, Husam Abdel-Qadir, Hadas D Fischer, Ying Liu, Ximena Camacho, Eitan Amir, Peter C Austin, Douglas S Lee
Purpose To assess prechemotherapy cardiac imaging practices in relation to patients' heart failure (HF) risk. Methods We performed a population-based retrospective cohort study of women receiving chemotherapy for early-stage breast cancer in Ontario between 2007 and 2012. We surveyed for baseline cardiac imaging 6 months before chemotherapy or within 30 days thereafter. The proportion of patients who underwent imaging and cumulative incidence of major adverse cardiac event (MACE) rates was determined based on chemotherapy regimen and HF risk factors...
May 23, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29787359/response-adapted-therapy-in-aggressive-lymphoma-not-yet-ready-for-clinical-care
#10
Reid W Merryman, Ann S LaCasce
No abstract text is available yet for this article.
May 22, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29787358/targeting-b-cell-lymphoma-2-a-lethal-shortcut-in-del-17p-chronic-lymphocytic-leukemia
#11
Anthony Letai
No abstract text is available yet for this article.
May 22, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29787357/prophylactic-cranial-irradiation-versus-observation-in-radically-treated-stage-iii-non-small-cell-lung-cancer-a-randomized-phase-iii-nvalt-11-dlcrg-02-study
#12
Dirk De Ruysscher, Anne-Marie C Dingemans, John Praag, Jose Belderbos, Caroline Tissing-Tan, Judith Herder, Tjeerd Haitjema, Fred Ubbels, Frank Lagerwaard, Sherif Y El Sharouni, Jos A Stigt, Egbert Smit, Harm van Tinteren, Vincent van der Noort, Harry J M Groen
Purpose The purpose of the current study was to investigate whether prophylactic cranial irradiation (PCI) reduces the incidence of symptomatic brain metastases in patients with stage III non-small-cell lung cancer (NSCLC) treated with curative intention. Patients and Methods Patients with stage III NSCLC-staged with a contrast-enhanced brain computed tomography or magnetic resonance imaging-were randomly assigned to either observation or PCI after concurrent/sequential chemoradiotherapy with or without surgery...
May 22, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29787356/selection-of-optimal-adjuvant-chemotherapy-and-targeted-therapy-for-early-breast-cancer-asco-clinical-practice-guideline-focused-update
#13
Neelima Denduluri, Mariana Chavez-MacGregor, Melinda L Telli, Andrea Eisen, Stephanie L Graff, Michael J Hassett, Jamie N Holloway, Arti Hurria, Tari A King, Gary H Lyman, Ann H Partridge, Mark R Somerfield, Maureen E Trudeau, Antonio C Wolff, Sharon H Giordano
Purpose To update key recommendations of the ASCO guideline adaptation of the Cancer Care Ontario guideline on the selection of optimal adjuvant chemotherapy regimens for early breast cancer and adjuvant targeted therapy for breast cancer. Methods An Expert Panel conducted targeted systematic literature reviews guided by a signals approach to identify new, potentially practice-changing data that might translate to revised practice recommendations. Results The Expert Panel reviewed phase III trials that evaluated adjuvant capecitabine after completion of standard preoperative anthracycline- and taxane-based combination chemotherapy by patients with early-stage breast cancer HER2-negative breast cancer with residual invasive disease at surgery; the addition of 1 year of adjuvant pertuzumab to combination chemotherapy and trastuzumab for patients with early-stage, HER2-positive breast cancer; and the use of neratinib as extended adjuvant therapy for patients after combination chemotherapy and trastuzumab-based adjuvant therapy with early-stage, HER2-positive breast cancer...
May 22, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29782209/practical-assessment-and-management-of-vulnerabilities-in-older-patients-receiving-chemotherapy-asco-guideline-for-geriatric-oncology
#14
Supriya G Mohile, William Dale, Mark R Somerfield, Mara A Schonberg, Cynthia M Boyd, Peggy S Burhenn, Beverly Canin, Harvey Jay Cohen, Holly M Holmes, Judith O Hopkins, Michelle C Janelsins, Alok A Khorana, Heidi D Klepin, Stuart M Lichtman, Karen M Mustian, William P Tew, Arti Hurria
Purpose To provide guidance regarding the practical assessment and management of vulnerabilities in older patients undergoing chemotherapy. Methods An Expert Panel was convened to develop clinical practice guideline recommendations based on a systematic review of the medical literature. Results A total of 68 studies met eligibility criteria and form the evidentiary basis for the recommendations. Recommendations In patients ≥ 65 years receiving chemotherapy, geriatric assessment (GA) should be used to identify vulnerabilities that are not routinely captured in oncology assessments...
May 21, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29782208/optimal-radical-therapy-for-localized-prostate-cancer-recreation-of-the-self-fulfilling-prophecy-with-combination-brachytherapy
#15
Daniel E Spratt, Peter R Carroll
No abstract text is available yet for this article.
May 21, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29775389/systematic-review-of-the-impact-of-cancer-survivorship-care-plans-on-health-outcomes-and-health-care-delivery
#16
Paul B Jacobsen, Antonio P DeRosa, Tara O Henderson, Deborah K Mayer, Chaya S Moskowitz, Electra D Paskett, Julia H Rowland
Purpose Numerous organizations recommend that patients with cancer receive a survivorship care plan (SCP) comprising a treatment summary and follow-up care plans. Among current barriers to implementation are providers' concerns about the strength of evidence that SCPs improve outcomes. This systematic review evaluates whether delivery of SCPs has a positive impact on health outcomes and health care delivery for cancer survivors. Methods Randomized and nonrandomized studies evaluating patient-reported outcomes, health care use, and disease outcomes after delivery of SCPs were identified by searching MEDLINE, Embase, PsycINFO, Cumulative Index to Nursing and Allied Health Literature, and Cochrane Library...
May 18, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29768119/exploratory-analysis-of-brigatinib-activity-in-patients-with-anaplastic-lymphoma-kinase-positive-non-small-cell-lung-cancer-and-brain-metastases-in-two-clinical-trials
#17
D Ross Camidge, Dong-Wan Kim, Marcello Tiseo, Corey J Langer, Myung-Ju Ahn, Alice T Shaw, Rudolf M Huber, Maximilian J Hochmair, Dae Ho Lee, Lyudmila A Bazhenova, Kathryn A Gold, Sai-Hong Ignatius Ou, Howard L West, William Reichmann, Jeff Haney, Tim Clackson, David Kerstein, Scott N Gettinger
Purpose In patients with crizotinib-treated, anaplastic lymphoma kinase gene ( ALK)-rearranged non-small-cell lung cancer (ALK-positive NSCLC), initial disease progression often occurs in the CNS. We evaluated brigatinib, a next-generation ALK inhibitor, in patients with ALK-positive NSCLC with brain metastases. Patients and Methods Patients with ALK-positive NSCLC received brigatinib (90 to 240 mg total daily) in a phase I/II trial (phI/II; ClinicalTrials.gov identifier: NCT01449461) and in the subsequent randomized phase II trial ALTA (ALK in Lung Cancer Trial of AP26113; ClinicalTrials...
May 16, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29768118/final-overall-survival-analysis-from-a-study-comparing-first-line-crizotinib-with-chemotherapy-results-from-profile-1014
#18
Benjamin J Solomon, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari, Yiyun Tang, Keith D Wilner, Fiona Blackhall, Tony S Mok
Purpose The phase III PROFILE 1014 trial compared crizotinib with chemotherapy as first-line treatment in patients with anaplastic lymphoma kinase (ALK) -positive advanced nonsquamous non-small-cell lung cancer. Here, we report the final overall survival (OS) results. Patients and Methods Patients were randomly assigned to receive oral crizotinib 250 mg twice daily (n = 172) or intravenous pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2 or carboplatin (area under the concentration-time curve of 5 to 6 mg·mL/min) every 3 weeks for a maximum of six cycles (n = 171)...
May 16, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29763342/molecular-testing-guideline-for-the-selection-of-patients-with-lung-cancer-for-targeted-therapy
#19
Mehmet Sitki Copur, David Crockett, Dron Gauchan, Ryan Ramaekers, Kris Mleczko
No abstract text is available yet for this article.
May 15, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29763341/reply-to-m-s-copur-et-al
#20
Gregory P Kalemkerian, Navneet Narula
No abstract text is available yet for this article.
May 15, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
journal
journal
20146
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"